Figure 4.

Perturbation studies confirm subtype-specific therapeutic vulnerabilities in prostate cancer cell lines. (a) Dose-response curves showing the effect of Torin2 (mTOR inhibitor), antimycin (oxidative phosphorylation inhibitor), and GSK-J4 (histone demethylase inhibitor) on the viability of AR-null and AR-positive cell lines. n = at least three biological replicates. (b) Bar graphs summarizing the effective drug concentration 50% (EC₅₀) of Torin2, antimycin, and GSK-J4 measured in the PC cell lines.